688197 首药控股
已收盘 03-02 15:00:01
资讯
新帖
简况
每周股票复盘：首药控股（688197）董事李庭因股东单位内部安排离任
证券之星 · 03-01 03:13
每周股票复盘：首药控股（688197）董事李庭因股东单位内部安排离任
首药控股（688197）披露董事离任公告，2月27日股价上涨0.74%
证券之星 · 02-27
首药控股（688197）披露董事离任公告，2月27日股价上涨0.74%
首药控股（688197）披露核心技术人员退休离任公告，2月24日股价下跌3.84%
中金财经 · 02-24
首药控股（688197）披露核心技术人员退休离任公告，2月24日股价下跌3.84%
首药控股跌3.84% 2022年上市募15亿中信建投保荐
中金财经 · 02-24
首药控股跌3.84% 2022年上市募15亿中信建投保荐
首药控股2026年关注点：业绩增长与核心产品审评进展
经济观察网 · 02-13
首药控股2026年关注点：业绩增长与核心产品审评进展
每周股票复盘：首药控股（688197）SY-9453获临床试验批准
证券之星 · 02-08
每周股票复盘：首药控股（688197）SY-9453获临床试验批准
首药控股(688197.SH)：MAT2A抑制剂SY-9453获得药物临床试验批准通知书
智通财经 · 02-04
首药控股(688197.SH)：MAT2A抑制剂SY-9453获得药物临床试验批准通知书
首药控股公布国际专利申请：“一种激酶抑制剂的制备方法”
证券之星 · 01-31
首药控股公布国际专利申请：“一种激酶抑制剂的制备方法”
首药控股跌1.8% 2022年上市募15亿
中金财经 · 01-06
首药控股跌1.8% 2022年上市募15亿
首药控股跌4.13% 前三季亏1.55亿2022年上市募15亿
中金财经 · 2025-12-26
首药控股跌4.13% 前三季亏1.55亿2022年上市募15亿
首药控股筹划发行H股并在香港联交所上市
中金财经 · 2025-12-14
首药控股筹划发行H股并在香港联交所上市
首药控股(688197.SH)筹划境外发行股份(H股)并在香港联交所上市
智通财经网 · 2025-12-12
首药控股(688197.SH)筹划境外发行股份(H股)并在香港联交所上市
破发连亏股首药控股前三季亏1.55亿 2022年上市募15亿
中金财经 · 2025-12-11
破发连亏股首药控股前三季亏1.55亿 2022年上市募15亿
12月2日首药控股跌5.25%，鹏华医药科技股票A基金重仓该股
证券之星 · 2025-12-02
12月2日首药控股跌5.25%，鹏华医药科技股票A基金重仓该股
11月7日首药控股跌5.46%，鹏华医药科技股票A基金重仓该股
证券之星 · 2025-11-07
11月7日首药控股跌5.46%，鹏华医药科技股票A基金重仓该股
每周股票复盘：首药控股（688197）股东户数增13.7%，前三季营收降47.37%
证券之星 · 2025-11-02
每周股票复盘：首药控股（688197）股东户数增13.7%，前三季营收降47.37%
首药控股公布国际专利申请：“一种抑制剂杂环化合物”
证券之星 · 2025-11-02
首药控股公布国际专利申请：“一种抑制剂杂环化合物”
图解首药控股三季报：第三季度单季净利润同比增长11.78%
证券之星 · 2025-10-30
图解首药控股三季报：第三季度单季净利润同比增长11.78%
首药控股（688197）披露召开2025年第三季度业绩说明会公告，10月30日股价下跌2.39%
中金财经 · 2025-10-30
首药控股（688197）披露召开2025年第三季度业绩说明会公告，10月30日股价下跌2.39%
首药控股(688197)9月30日股东户数0.51万户，较上期增加13.7%
证券之星 · 2025-10-30
首药控股(688197)9月30日股东户数0.51万户，较上期增加13.7%
加载更多
公司概况
公司名称：
首药控股(北京)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-23
主营业务：
首药控股(北京)股份有限公司的主营业务是从事小分子靶向创新药的研发。公司的主要产品是肿瘤和糖尿病药物。
发行价格：
39.90
{"stockData":{"symbol":"688197","market":"SH","secType":"STK","nameCN":"首药控股","latestPrice":35.84,"timestamp":1772434801000,"preClose":37,"halted":0,"volume":1113029,"delay":0,"changeRate":-0.0314,"floatShares":64004900,"shares":149000000,"eps":-1.3901,"marketStatus":"已收盘","change":-1.16,"latestTime":"03-02 15:00:01","open":37,"high":37,"low":35.45,"amount":39958700,"amplitude":0.0419,"askPrice":35.88,"askSize":1,"bidPrice":35.84,"bidSize":9,"shortable":0,"etf":0,"ttmEps":-1.3901,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772501400000},"marketStatusCode":5,"adr":0,"adjPreClose":37,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772415000000,1772422200000],[1772427600000,1772434800000]],"highLimit":40.7,"lowLimit":33.3,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":148719343,"isCdr":false,"pbRate":8.15,"roa":"--","roe":"--","epsLYR":-1.43,"committee":0.12426,"marketValue":5330000000,"turnoverRate":0.0174,"status":1,"afterMarket":{"amount":0,"volume":0,"close":35.84,"buyVolume":629,"sellVolume":0,"time":1772436837558,"indexStatus":"已收盘 03-02 15:30:00","preClose":37},"floatMarketCap":2294000000},"requestUrl":"/m/hq/s/688197","defaultTab":"news","newsList":[{"id":"2616457098","title":"每周股票复盘：首药控股（688197）董事李庭因股东单位内部安排离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2616457098","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616457098?lang=zh_cn&edition=full","pubTime":"2026-03-01 03:13","pubTimestamp":1772305991,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，首药控股报收于37.0元，较上周的38.85元下跌4.76%。本周关注点公司公告汇总：董事李庭因股东单位内部管理安排辞任公司董事职务公司公告汇总首药控股（北京）股份有限公司董事李庭女士因股东单位北京亦庄国际投资发展有限公司的内部管理安排，申请辞去公司第二届董事会董事职务，辞任自2026年2月26日生效。截至公告日，李庭女士未直接或间接持有公司股份，不存在未履行的公开承诺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2614093850","title":"首药控股（688197）披露董事离任公告，2月27日股价上涨0.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614093850","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614093850?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:43","pubTimestamp":1772206991,"startTime":"0","endTime":"0","summary":"近日，首药控股（北京）股份有限公司发布《关于董事离任的公告》。公告显示，公司董事李庭女士因股东单位北京亦庄国际投资发展有限公司的内部管理安排，申请辞去公司第二届董事会董事职务，辞任自2026年2月26日生效。李庭女士在任期间与公司、董事会及各专门委员会无意见分歧，亦无应披露未披露事项。截至公告日，李庭女士未直接或间接持有公司股份，不存在未履行的公开承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700043541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2613713843","title":"首药控股（688197）披露核心技术人员退休离任公告，2月24日股价下跌3.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613713843","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613713843?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:26","pubTimestamp":1771932390,"startTime":"0","endTime":"0","summary":"公告显示，公司核心技术人员HONG LUO因年龄原因申请退休，退休后不再担任公司任何职务。罗鸿先生出生于1959年，曾任公司副总经理、总经理等职，未持有公司股份。公司已与其完成工作交接，研发团队结构完整，后备人员充足，其离任不影响公司技术研发和日常运营，不构成重大不利影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260224/32024362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2613990207","title":"首药控股跌3.84% 2022年上市募15亿中信建投保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2613990207","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613990207?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:21","pubTimestamp":1771924889,"startTime":"0","endTime":"0","summary":"中国经济网北京2月24日讯 首药控股 今日股价收报37.36元，跌幅3.84%。目前该股处于破发状态。 首药控股于2022年3月23日在上交所科创板上市，发行价格为39.90元/股，公开发行股数为3718.00万股，占发行后总股本的比例为25.00%，保荐机构为中信建投证券股份有限公司，保荐代表人为杨慧泽、李彦芝。 首药控股上市发行费用总额为1.10亿元，中信建投证券股份有限公司获得保荐及承销费用9089.57万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260224/32023780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","601066","BK0276","688197"],"gpt_icon":0},{"id":"2611189365","title":"首药控股2026年关注点：业绩增长与核心产品审评进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2611189365","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611189365?lang=zh_cn&edition=full","pubTime":"2026-02-13 12:05","pubTimestamp":1770955500,"startTime":"0","endTime":"0","summary":"经济观察网首药控股-U(688197)2026年需关注财务披露及核心产品研发进展。业绩经营情况公司于2026年1月30日披露2025年业绩快报，显示营业收入866.76万元，同比增长119.88%，亏损同比收窄。正 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260213/c674790854.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260213/c674790854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2609264815","title":"每周股票复盘：首药控股（688197）SY-9453获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2609264815","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609264815?lang=zh_cn&edition=full","pubTime":"2026-02-08 03:11","pubTimestamp":1770491470,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，首药控股报收于36.3元，较上周的35.77元上涨1.48%。本周，首药控股2月2日盘中最高价报37.49元。本周关注点公司公告汇总：SY-9453胶囊获药物临床试验批准通知书。公司公告汇总首药控股（北京）股份有限公司自愿披露，其收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，SY-9453胶囊单药用于治疗甲基硫腺苷磷酸化酶纯合缺失的局部晚期或转移性实体瘤的临床试验申请获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2608735285","title":"首药控股(688197.SH)：MAT2A抑制剂SY-9453获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2608735285","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608735285?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:40","pubTimestamp":1770198027,"startTime":"0","endTime":"0","summary":"智通财经APP讯，首药控股(688197.SH)发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，SY-9453胶囊单药用于治疗甲基硫腺苷磷酸化酶(MTAP)纯合缺失的局部晚期或转移性实体瘤的临床试验申请获得批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4563","688197","BK4503","SY","BK4077","BK0239"],"gpt_icon":0},{"id":"2607220860","title":"首药控股公布国际专利申请：“一种激酶抑制剂的制备方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2607220860","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607220860?lang=zh_cn&edition=full","pubTime":"2026-01-31 06:45","pubTimestamp":1769813144,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示首药控股（688197）公布了一项国际专利申请，专利名为“一种激酶抑制剂的制备方法”，专利申请号为PCT/CN2025/110439，国际公布日为2026年1月29日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来首药控股已公布的国际专利申请3个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了1.08亿元，同比增1%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013100005182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2601472898","title":"首药控股跌1.8% 2022年上市募15亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2601472898","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601472898?lang=zh_cn&edition=full","pubTime":"2026-01-06 17:29","pubTimestamp":1767691751,"startTime":"0","endTime":"0","summary":"中国经济网北京1月6日讯 首药控股 今日股价收报36.53元，跌幅1.80%。 首药控股于2022年3月23日在上交所科创板上市，发行价格为39.90元/股，公开发行股数为3718.00万股，占发行后总股本的比例为25.00%，保荐机构为中信建投证券股份有限公司，保荐代表人为杨慧泽、李彦芝。 首药控股上市发行费用总额为1.10亿元，中信建投证券股份有限公司获得保荐及承销费用9089.57万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260106/31919551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2594260544","title":"首药控股跌4.13% 前三季亏1.55亿2022年上市募15亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2594260544","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594260544?lang=zh_cn&edition=full","pubTime":"2025-12-26 17:19","pubTimestamp":1766740755,"startTime":"0","endTime":"0","summary":"中国经济网北京12月26日讯 首药控股 今日股价收报35.30元，跌幅4.13%。目前该股处于破发状态。 首药控股上市发行费用总额为1.10亿元，中信建投证券股份有限公司获得保荐及承销费用9089.57万元。 首药控股近年连续亏损，2021年至2024年，公司归属于上市公司股东的净利润分别为-1.449亿元、-1.738亿元、-1.856亿元、-2.119亿元，归属于上市公司股东的扣除非经常性损益的净利润分别为-1.626亿元、-1.990亿元、-1.994亿元、-2.350亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251226/31895117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2591659935","title":"首药控股筹划发行H股并在香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2591659935","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591659935?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:12","pubTimestamp":1765671156,"startTime":"0","endTime":"0","summary":"中访网数据 首药控股(北京)股份有限公司于今日发布公告，宣布正在筹划发行境外股份(H股)并在香港联合交易所有限公司主板上市的相关事项。 根据公告，公司目前正与相关中介机构就本次H股上市的具体推进工作进行商讨，包括发行规模、定价机制、时间安排等在内的诸多细节尚未最终确定。公司明确表示，本次H股上市计划不会导致公司控股股东和实际控制人发生变更。 本次发行上市计划需履行一系列严格的审议和监管程序。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251214/31864517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2590282572","title":"首药控股(688197.SH)筹划境外发行股份(H股)并在香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2590282572","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590282572?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:46","pubTimestamp":1765532765,"startTime":"0","endTime":"0","summary":"智通财经APP讯，首药控股(688197.SH)发布公告，公司为进一步提升核心竞争力与品牌影响力，充分借助国际资本市场的资源与机制优势，优化资本结构，拓宽多元融资渠道，正在筹划发行境外股份(H股)并在香港联合交易所有限公司(以下简称“香港联交所”)上市事宜。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"首药控股(688197.SH)筹划境外发行股份(H股)并在香港联交所上市","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2590593499","title":"破发连亏股首药控股前三季亏1.55亿 2022年上市募15亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2590593499","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590593499?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:07","pubTimestamp":1765440424,"startTime":"0","endTime":"0","summary":"中国经济网北京12月11日讯 首药控股 近日发布2025年第三季度报告显示，2025年第三季度，公司归属于上市公司股东的净利润-5039.54万元；归属于上市公司股东的扣除非经常性损益的净利润-5458.78万元。 首药控股上市发行费用总额为1.10亿元，中信建投证券股份有限公司获得保荐及承销费用9089.57万元。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202512/11/20251211461485.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202512/11/20251211461485.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251211/31859231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2588080561","title":"12月2日首药控股跌5.25%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588080561","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588080561?lang=zh_cn&edition=full","pubTime":"2025-12-02 15:32","pubTimestamp":1764660746,"startTime":"0","endTime":"0","summary":"证券之星消息，12月2日首药控股跌5.25%，收盘报39.18元，换手率2.37%，成交量1.52万手，成交额6013.65万元。该股为医药、创新药概念热股。重仓首药控股的公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为19.21亿元，最新净值1.7501，较上一交易日下跌0.56%，近一年上涨57.44%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200017304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","BK0239","159938","688197","BK1515","09939"],"gpt_icon":0},{"id":"2581072660","title":"11月7日首药控股跌5.46%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581072660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581072660?lang=zh_cn&edition=full","pubTime":"2025-11-07 16:17","pubTimestamp":1762503441,"startTime":"0","endTime":"0","summary":"证券之星消息，11月7日首药控股跌5.46%，收盘报38.98元，换手率2.41%，成交量1.54万手，成交额6107.9万元。该股为医药、创新药概念热股。重仓首药控股的公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为19.21亿元，最新净值1.7839，较上一交易日下跌0.2%，近一年上涨62.2%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700024837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09939","BK1574","BK1515","159938","688197","BK0239"],"gpt_icon":0},{"id":"2580477998","title":"每周股票复盘：首药控股（688197）股东户数增13.7%，前三季营收降47.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580477998","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580477998?lang=zh_cn&edition=full","pubTime":"2025-11-02 07:30","pubTimestamp":1762039839,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，首药控股报收于41.68元，较上周的39.9元上涨4.46%。本周，首药控股10月31日盘中最高价报41.96元。股本股东变化股东户数变动截至2025年9月30日，首药控股股东户数为5146户，较6月30日增加620户，增幅13.7%。业绩披露要点财务报告首药控股2025年三季报显示，前三季度主营收入200.0万元，同比下降47.37%；归母净利润-1.55亿元，同比上升3.26%；扣非净利润-1.69亿元，同比上升1.87%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197"],"gpt_icon":0},{"id":"2580647149","title":"首药控股公布国际专利申请：“一种抑制剂杂环化合物”","url":"https://stock-news.laohu8.com/highlight/detail?id=2580647149","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580647149?lang=zh_cn&edition=full","pubTime":"2025-11-02 05:21","pubTimestamp":1762032073,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示首药控股（688197）公布了一项国际专利申请，专利名为“一种抑制剂杂环化合物”，专利申请号为PCT/CN2025/090983，国际公布日为2025年10月30日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来首药控股已公布的国际专利申请5个，与去年同期持平。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了1.08亿元，同比增1%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2579145949","title":"图解首药控股三季报：第三季度单季净利润同比增长11.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579145949","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579145949?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:53","pubTimestamp":1761825205,"startTime":"0","endTime":"0","summary":"证券之星消息，首药控股2025年三季报显示，前三季度公司主营收入200.0万元，同比下降47.37%；归母净利润-1.55亿元，同比上升3.26%；扣非净利润-1.69亿元，同比上升1.87%；其中2025年第三季度，公司单季度主营收入0.0万元，单季度归母净利润-5039.54万元，同比上升11.78%；单季度扣非净利润-5458.78万元，同比上升12.19%；负债率14.12%，投资收益675.63万元，财务费用-49.59万元。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000040381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197"],"gpt_icon":0},{"id":"2579622119","title":"首药控股（688197）披露召开2025年第三季度业绩说明会公告，10月30日股价下跌2.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579622119","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579622119?lang=zh_cn&edition=full","pubTime":"2025-10-30 18:14","pubTimestamp":1761819267,"startTime":"0","endTime":"0","summary":"近日，首药控股(北京)股份有限公司发布公告称，公司将于2025年11月18日上午9:00-10:00通过上海证券交易所上证路演中心网络文字互动方式召开2025年第三季度业绩说明会，介绍公司前三季度运营情况、创新药物研发进展及未来发展理念。投资者可于11月18日登录上证路演中心在线参与，或于11月11日至17日16:00前通过上证路演中心“提问预征集”栏目或公司邮箱shouyaoholding@163.com提前提交问题。会后可通过上证路演中心查看会议内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251030/31751605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2579118608","title":"首药控股(688197)9月30日股东户数0.51万户，较上期增加13.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579118608","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579118608?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:28","pubTimestamp":1761816498,"startTime":"0","endTime":"0","summary":"证券之星消息，近日首药控股披露，截至2025年9月30日公司股东户数为5146.0户，较6月30日增加620.0户，增幅为13.7%。户均持股数量由上期的3.29万股减少至2.89万股，户均持股市值为130.34万元。在化学制药行业个股中，首药控股股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.43万户。从股价来看，2025年6月30日至2025年9月30日，首药控股区间涨幅为24.59%，在此期间股东户数增加620.0户，增幅为13.7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000033122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772479204927,"stockEarnings":[{"period":"1week","weight":-0.0775},{"period":"1month","weight":0.002},{"period":"3month","weight":-0.0852},{"period":"6month","weight":-0.2416},{"period":"1year","weight":0.0284},{"period":"ytd","weight":0.0317}],"compareEarnings":[{"period":"1week","weight":0.0246},{"period":"1month","weight":0.0157},{"period":"3month","weight":0.0731},{"period":"6month","weight":0.0968},{"period":"1year","weight":0.2595},{"period":"ytd","weight":0.0539}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"首药控股(北京)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"5146人(较上一季度增加13.70%)","perCapita":"12437股","listingDate":"2022-03-23","address":"北京市大兴区北京经济技术开发区荣华中路10号1幢19层1单元2202-2号","registeredCapital":"14871万元","survey":" 首药控股(北京)股份有限公司的主营业务是从事小分子靶向创新药的研发。公司的主要产品是肿瘤和糖尿病药物。","listedPrice":39.9},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"首药控股(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供首药控股(688197)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"首药控股,688197,首药控股股票,首药控股股票老虎,首药控股股票老虎国际,首药控股行情,首药控股股票行情,首药控股股价,首药控股股市,首药控股股票价格,首药控股股票交易,首药控股股票购买,首药控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"首药控股(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供首药控股(688197)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}